A human‐human hybridoma system based on a fast‐growing mutant of the ARH‐77 plasma cell leukemia‐derived line

Publisher Website
Google Scholar
Abstract
A rapidly‐growing, HAT‐sensitive cell line LICR‐LON‐HMy2 has been derived from the ARH‐77 human plasma cell leukemia‐derived line. It lacks the enzyme hypoxanthine phosphoribosyltransferase (EC 2.4.2.8). Hybrids have been reproducibly made for more than a year and in independent laboratories with lymphocytes from tonsils, lymph nodes and peripheral blood and tonsil lymphocytes cultured with antigens. The parent line and hybrids are very robust in culture and double in 20‐30 h. Hybrids clone easily and have stable karyotypes, most with modal numbers in the sixties. Stable Ig secretion patterns have been observed over 20‐30 passages, and after cloning. It was estimated that about half the hybrids produce new immunoglobulin chains in addition to the parent cell line's IgG1 (× light chain). High, but not limiting, density hybridoma cultures (approximately 5 × 105 cells/ml) typically produce 0.25‐2 μg/ml immunoglobulin per day, but some hybrids produce more. A high‐secreting variant of LICR‐LON‐HMy2 has been derived. The LICR‐LON‐HMy2 line is human and is distinct from the HAT‐sensitive human B cell‐lines SKO‐007 and GM 1500‐6TG A1 2. It is available for distribution.